Karim Fizazi

Karim Fizazi

Auto-generated profile, based on publicly available information

Karim Fizazi

Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in The Lancet
Verified
Journal Article
Closed access
KFKarim Fizazi
Karim Fizazi
MCMichael Carducci
Michael Carducci
MSMatthew Smith
Matthew Smith
RDRonaldo Damião
Ronaldo Damião
JBJanet Brown
Janet Brown
CGCarsten Goessl
Carsten Goessl

1 April 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KFKarim Fizazi
Karim Fizazi
ALAllan Lipton
Allan Lipton
XMXavier Mariette
Xavier Mariette
JBJean-Jacques Body
Jean-Jacques Body
YRYasmin Rahim
Yasmin Rahim
SJSusie Jun
Susie Jun
Purpose: Patients with bone metastases and elevated urinary N-telopeptide (uNTx), representing excessive bone resorption, are at increased risk for skeletal-related events (SREs), cancer progression, and death. Osteoclast-mediated bone resorption is regulated by RANKL. We evaluated the effect of denosumab, a fully human monoclonal antibody against RANKL, in patients with bone metastases and elevated uNTx levels despite ongoing intravenous (IV) bisphosphonate (BP) therapy. Patients and Methods: Eligible patients had histologically confirmed malignancy, ≥ 1 bone metastases, and uNTx levels higher than 50 nmol/L bone collagen equivalents (BCE)/mM creatinine despite IV BPs. They were stratified by tumor type and screening uNTx levels (50 to 100 or > 100 nmol/L BCE/mM creatinine), and randomly assigned to continue IV BPs every 4 weeks or receive subcutaneous denosumab 180 mg every 4 weeks or every 12 weeks. Results: Among 111 patients accrued, the primary end point of uNTx levels lower than 50 nmol/L BCE/mM creatinine (uNTx < 50) at week 13 was achieved by 49 (71%) of 69 patients in the denosumab arms, compared with 10 (29%) of 35 patients in the IV BP arm (P < .001). The proportion of patients with uNTx lower than 50 was maintained at week 25 (64% denosumab arms; 37% IV BP arm; P = .01). The incidence of SREs was six (8%) of 73 and six (17%) of 35 in the denosumab group and IV BP group, respectively. Rates of adverse events were similar between treatment groups. Conclusion: Among patients with elevated uNTx despite ongoing IV BP therapy, denosumab normalized uNTx levels more frequently than the continuation of IV BP. Fewer patients receiving denosumab experienced on-study SREs than those receiving IV BPs.

15 May 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KFKarim Fizazi
Karim Fizazi
STSergei Tjulandin
Sergei Tjulandin
RSRoberto Salvioni
Roberto Salvioni
JGJosé R. Germà-Lluch
José R. Germà-Lluch
JBJeannine Bouzy
Jeannine Bouzy
CMCedric Mahé
Cedric Mahé
PURPOSE: To assess the value of postsurgery chemotherapy in patients with disseminated nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line cisplatin-based chemotherapy. PATIENTS AND METHODS: The outcome of 238 patients was reviewed. Tumor markers had normalized in all patients before resection. A multivariate analysis of survival was performed on 146 patients. RESULTS: The 5-year progression-free survival (PFS) rate was 64% and the 5-year overall survival (OS) rate was 73%. Three factors were independently associated with both PFS and OS: complete resection (P < .001), < 10% of viable malignant cells (P = .001), and a good International Germ Cell Consensus Classification (IGCCC) group (P = .01). Patients were assigned to one of three risk groups: those with no risk factors (favorable group), those with one risk factor (intermediate group), and those with two or three risk factors (poor-risk group). The 5-year OS rate was 100%, 83%, and 51%, respectively (P < .001). The 5-year PFS rate was 69% (95% confidence interval [CI], 62% to 76%) and 52% (95% CI, 40% to 64%) in postoperative chemotherapy recipients and nonrecipients, respectively (P < .001). No significant difference was detected in 5-year OS rates. After adjustment on the three prognostic factors, postoperative chemotherapy was associated with a significantly better PFS (P < .001) but not with better OS. Patients in the favorable risk group had a 100% 5-year OS, with or without postoperative chemotherapy. Postoperative chemotherapy appeared beneficial in both PFS (P < .001) and OS (P = .02) in the intermediate-risk group but was not statistically beneficial in the poor-risk group. CONCLUSION: A complete resection may be more critical than recourse to postoperative chemotherapy in the setting of postchemotherapy viable malignant NSGCT. Immediate postoperative chemotherapy or surveillance alone with chemotherapy at relapse may be reasonable options depending on the completeness of resection, IGCCC group, and percent of viable cells. Validation is necessary.

10 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KFKarim Fizazi
Karim Fizazi
CHCelestia S. Higano
Celestia S. Higano
JNJoel B. Nelson
Joel B. Nelson
MGMartin Gleave
Martin Gleave
KMKurt Miller
Kurt Miller
JMJudd W. Moul
Judd W. Moul
Purpose: As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC). Patients and Methods: In this randomized, double-blind, placebo-controlled, phase III study, patients received intravenous docetaxel 75 mg/m2 on day 1 of 21-day cycles plus oral zibotentan 10 mg or placebo once daily. The primary end point was overall survival (OS). Secondary end points included time to pain and prostate-specific antigen (PSA) progression, pain and PSA response, progression-free survival, health-related quality of life, and safety. Results: A total of 1,052 patients received study treatment (docetaxel-zibotentan, n = 524; docetaxel-placebo, n = 528). At the time of data cutoff, there had been 277 and 280 deaths, respectively. There was no difference in OS for patients receiving docetaxel-zibotentan compared with those receiving docetaxel-placebo (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P = .963). No significant differences were observed on secondary end points, including time to pain progression (median 9.3 v 10.0 months, respectively) or pain response (odds ratio, 0.84; 95% CI, 0.61 to 1.16; P = .283). The median time to death was 20.0 and 19.2 months for the zibotentan and placebo groups, respectively. The most commonly reported adverse events in zibotentan-treated patients were peripheral edema (52.7%), diarrhea (35.4%), alopecia (33.9%), and nausea (33.3%). Conclusion: Docetaxel plus zibotentan 10 mg/d did not result in a significant improvement in OS compared with docetaxel plus placebo in patients with metastatic CRPC.

1 August 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
KFKarim Fizazi
Karim Fizazi
CMChristophe Massard
Christophe Massard
PBPetri Bono
Petri Bono
RJRobert Jones
Robert Jones
VKVesa Kataja
Vesa Kataja
MMMika Mustonen
Mika Mustonen

1 January 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
KFK. Fizazi
K. Fizazi
JBJ.S. De Bono
J.S. De Bono
AFA. Flechon
A. Flechon
AHA. Heidenreich
A. Heidenreich
EVE. Voog
E. Voog
GHG.R. Hudes
G.R. Hudes